SG Americas Securities LLC Takes $691,000 Position in Perrigo Company plc (NYSE:PRGO)

SG Americas Securities LLC bought a new position in shares of Perrigo Company plc (NYSE:PRGOFree Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 26,868 shares of the company’s stock, valued at approximately $691,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc purchased a new position in shares of Perrigo during the 4th quarter worth about $45,000. GAMMA Investing LLC raised its stake in Perrigo by 93.7% during the fourth quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $49,000 after purchasing an additional 929 shares during the period. Central Pacific Bank Trust Division boosted its holdings in shares of Perrigo by 33.3% in the 4th quarter. Central Pacific Bank Trust Division now owns 2,000 shares of the company’s stock valued at $51,000 after purchasing an additional 500 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Perrigo during the 3rd quarter valued at $56,000. Finally, KBC Group NV increased its holdings in shares of Perrigo by 25.1% during the 3rd quarter. KBC Group NV now owns 4,517 shares of the company’s stock worth $118,000 after buying an additional 905 shares during the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Jeffrey B. Kindler sold 17,598 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $28.27, for a total value of $497,495.46. Following the completion of the transaction, the director now owns 5,409 shares of the company’s stock, valued at approximately $152,912.43. This represents a 76.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PRGO. StockNews.com cut Perrigo from a “buy” rating to a “hold” rating in a report on Saturday, January 11th. Argus lowered Perrigo from a “buy” rating to a “hold” rating in a research note on Tuesday, January 14th. Finally, Piper Sandler downgraded shares of Perrigo from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $34.00 to $27.00 in a research report on Monday, January 6th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $35.00.

Get Our Latest Stock Analysis on Perrigo

Perrigo Trading Up 0.9 %

NYSE:PRGO opened at $24.90 on Friday. Perrigo Company plc has a 12 month low of $23.14 and a 12 month high of $33.46. The business’s 50-day moving average is $26.08 and its two-hundred day moving average is $26.61. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.56 and a quick ratio of 1.77. The firm has a market capitalization of $3.40 billion, a PE ratio of -21.28 and a beta of 0.53.

Perrigo (NYSE:PRGOGet Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.81 EPS for the quarter, hitting the consensus estimate of $0.81. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the company posted $0.64 EPS. Perrigo’s revenue for the quarter was down 3.2% on a year-over-year basis. Research analysts predict that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Profile

(Free Report)

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.

Recommended Stories

Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company plc (NYSE:PRGOFree Report).

Institutional Ownership by Quarter for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.